Expanded Access for Bulevirtide

Summary

The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Mageras A, Rodriguez N, Katzenstein C, Lee F, Alpert L, Branch AD, Zhang X, Dieterich DT, Kushner T. Novel Implementation of Hepatitis B to Hepatitis Delta Reflex Testing in a US Healthcare System. Am J Gastroenterol. 2026 Jul 1;121(7):1650-1658. doi: 10.14309/ajg.0000000000003688. Epub 2025 Jul 31.

Drugs

Indications